Prostate cancer is common all around the world. Hormonal therapy is the mainstay of therapy, howevercastration-resistant prostate cancer (CRPC) becomes a serious problem and needs further clinical trials withnovel agents. Novel agents like cabazitaxel, abireterone acetate or enzalutamide are encouraging but we do notknow which one is the best in metastatic CRPC. In here, treatment modalities for metastatic CRPC are discussedwitha mini-review of the literature.
(2015). Is it Time to Change the Control Placebo Arms in Phase III Trials of Metastatic Castration Resistant Prostate Cancer?. Asian Pacific Journal of Cancer Prevention, 16(14), 6167-6169.
MLA
. "Is it Time to Change the Control Placebo Arms in Phase III Trials of Metastatic Castration Resistant Prostate Cancer?". Asian Pacific Journal of Cancer Prevention, 16, 14, 2015, 6167-6169.
HARVARD
(2015). 'Is it Time to Change the Control Placebo Arms in Phase III Trials of Metastatic Castration Resistant Prostate Cancer?', Asian Pacific Journal of Cancer Prevention, 16(14), pp. 6167-6169.
VANCOUVER
Is it Time to Change the Control Placebo Arms in Phase III Trials of Metastatic Castration Resistant Prostate Cancer?. Asian Pacific Journal of Cancer Prevention, 2015; 16(14): 6167-6169.
)